Expert Perspectives on the Evolving Treatment Landscape of Multiple Myeloma - Episode 11

BCMA-Targeting Bispecifics in Relapsed/Refractory Multiple Myeloma

February 20, 2023

Sagar Lonial, MD, Amrita Krishnan, MD, Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center, Hana Safah, MD, Noopur S. Raje, MD

Hana Safah, MD, and Noopur Raje, MD, discuss data on BCMA-targeting bispecifics teclistamab and elrantamab for treatment of relapsed/refractory multiple myeloma.

EP. 1: Data Updates in the Frontline Treatment of Patients With Transplant-Eligible Multiple Myeloma

EP. 2: Considerations for Frontline Treatment in Transplant-Ineligible Multiple Myeloma

EP. 3: Defining Frailty in Multiple Myeloma for Optimal Treatment

EP. 4: Approaches to Treatment Duration in Newly-Diagnosed Multiple Myeloma

EP. 5: Relapse in Multiple Myeloma: Biochemical and Chemical

EP. 6: Data Updates in the Treatment of Relapsed Multiple Myeloma

EP. 7: Strategies for Treatment of Multiple Myeloma at Late Relapse

EP. 8: Quadruplet Combination Therapies in Relapsed Multiple Myeloma

EP. 9: Considerations for Treatment Decision-Making in Early-Relapse Multiple Myeloma

EP. 10: CD38 Monoclonal Antibodies for Early Relapsed Multiple Myeloma and the Risk of COVID Infection

Now Viewing

EP. 11: BCMA-Targeting Bispecifics in Relapsed/Refractory Multiple Myeloma

EP. 12: Retreatment with a BCMA-Targeting Bispecific for R/R MM

EP. 13: Data Updates on Immunotherapy Combinations in Multiple Myeloma

EP. 14: Targets in Multiple Myeloma: GPRC5D

EP. 15: Targets in Multiple Myeloma: FcRH5

EP. 16: Managing Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome in Multiple Myeloma

EP. 17: Preventing Infection in Patients with Multiple Myeloma During Treatment

EP. 18: Does Belantamab Have a Place in Multiple Myeloma Treatment?

EP. 19: Unmet Needs and Future Perspectives in Multiple Myeloma Care